TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2236458
Drug: Clomipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (mean dosage 165 +/- 19 mg/day, reduced from 270 +/- 20 mg/day)
Study: 2236458
Drug: Clomipramine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (initial dosage 270 +/- 20 mg/day)
Study: 27430425
Drug: sarolaner (Simparica™
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarolaner (Simparica™ Chewables) administered monthly for 3 months (2 to 4 mg/kg)
Study: 27430425
Drug: fluralaner (Bravecto®)
Normalized name: fluralaner Topical Solution [Bravecto]
DrugBank: Fluralaner (DB11414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluralaner (Bravecto®) administered as a single dose (25 to 56 mg/kg)
Study: 7548266
Drug: Gallopamil 150
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 150 mg daily
Study: 7548266
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg tid for 28 days
Study: 7036825
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g daily intake of oral erythromycin base
Study: 17617940
Drug: 2.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 g/d plant sterol supplementation
Study: 17617940
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d plant sterol supplementation
Study: 12162476
Drug: gatifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin (400 mg po 1 h)
Study: 12162476
Drug: oxycodone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone (5 mg po Q4H)
Study: 12162476
Drug: gatifloxacin/oxycodone regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin/oxycodone regimen
Study: 10658860
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (n = 14)
Study: 10658860
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (n = 16)
Study: 1481703
Drug: Implicit preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implicit preparation instruction
Study: 1481703
Drug: Explicit preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Explicit preparation instruction
Study: 1481703
Drug: Random presentation
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random presentation mode of preparation intervals
Study: 1481703
Drug: Blocked presentation
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocked presentation mode of preparation intervals
Study: 1481703
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of implicit/explicit instructions and random/blocked presentation modes
Study: 3969867
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 10 mg every 2 hours for 72 hours
Study: 18363889
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg for 4 days)
Study: 16797384
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention targeting specific barriers (e.g., poor nutritional knowledge, help needed with shopping or cooking, difficulty swallowing)
Study: 24645966
Drug: Single-dose (PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (PEG 4 L the day before the study)
Study: 24645966
Drug: Split-dose (2 L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose (2 L the day before and 2 L on the day of the procedure)
Study: 24645966
Drug: Low-volume (2 L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume (2 L PEG solution the day of the procedure)
Study: 16247428
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (c.i.v.) administration of rhG-CSF
Study: 16247428
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of rhG-CSF
Study: 3281489
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg/kg over 3 days)
Study: 3281489
Drug: Sulfadoxine-pyrimethamine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (single dose: 500 mg sulfadoxine and 25 mg pyrimethamine)
Study: 16717297
Drug: Nonpulsatile CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpulsatile CPB flow rates (2.4 L/min/m2 to either 1.8 or 3.0 L/min/m2)
Study: 15058375
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix derivative (EMD) combined with surgical treatment
Study: 9455714
Drug: Ranitidine 2
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2 mg/kg with Metoclopramide 0.2 mg/kg
Study: 9455714
Drug: Ranitidine 2
Normalized name: ranitidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2 mg/kg with Domperidone 0.3 mg/kg
Study: 9455714
Drug: Famotidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 0.5 mg/kg with Metoclopramide 0.2 mg/kg
Study: 9455714
Drug: Famotidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 0.5 mg/kg with Domperidone 0.3 mg/kg
Study: 2731781
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg/day
Study: 1103722
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg, 1-hour intravenous infusion)
Study: 1103722
Drug: Sisomicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin (1 mg/kg, 1-hour intravenous infusion)
Study: 1103722
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg/kg, 1-hour intravenous infusion)
Study: 1103722
Drug: All antibiotics
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antibiotics tested
Study: 27916398
Drug: Ruxolitinib 10
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 10 mg twice daily
Study: 27916398
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment)
Study: 26006222
Drug: Dex/Bup/Fen group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dex/Bup/Fen group (1 mL epidural dexmedetomidine 0.5 µg/kg)
Study: 26006222
Drug: Bup/Fen group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bup/Fen group (intrathecal hyperbaric bupivacaine 5 mg and epidural mixture of 10 mL plain bupivacaine 0.25 % and fentanyl 50 μg)
Study: 22674972
Drug: Nintendo Wii
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nintendo Wii Fit® balance exercise programme (12 supervised 30-min sessions, twice a week for 6-7 weeks)
Study: 18707821
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Study: 18707821
Drug: 8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Study: 15625041
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (medical counseling on diet and health without drug treatment)
Study: 11595000
Drug: PNU-142633 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-142633 (50 mg)
Study: 8061848
Drug: Spirapril 24
Normalized name: spirapril 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 24 mg once daily
Study: 31869474
Drug: Concurrent Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Exercise (CEX)
Study: 29210627
Drug: Nevirapine extended
Normalized name: Nevirapine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine extended release (NVP-XR) 400 mg once daily
Study: 29210627
Drug: Nevirapine immediate
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine immediate release (NVP-IR) 200 mg twice daily
Study: 26380444
Drug: Qianjin Kouchuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianjin Kouchuang Jiawei Granule (QKJG), 20 g each time, twice per day.
Study: 26380444
Drug: Kouyanqing Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kouyanqing Granule (KG), 20 g each time, twice per day.
Study: 26380444
Drug: QKJG vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QKJG vs KG at day 3 after treatment.
Study: 26380444
Drug: QKJG vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QKJG vs KG at day 7 after treatment.
Study: 26380444
Drug: QKJG vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QKJG vs KG at month 12 after treatment.
Study: 21525866
Drug: Prebiotic oligosaccharide
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic oligosaccharide mixture (15 or 30 g scGOS/lcFOS/pAOS daily)
Study: 18652320
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Estradiol Valerate 2 mg, qd for 20 days, followed by Medroxyprogesterone Acetate 4 mg, b.i.d for 10 days
Study: 12753987
Drug: 3-ml lidocaine-adrenaline
Normalized name: LIDOCAINE HCL 1% INJ 3ML SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-ml lidocaine-adrenaline injection before tonsillectomy
Study: 3551180
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (KABI fragment 2165) 1 X 2'500 anti-factor Xa IU
Study: 3551180
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 2 X 5'000 IU
Study: 3551180
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (KABI fragment 2165) 1 X 7'500 anti-factor Xa IU
Study: 20193834
Drug: OAC (warfarin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (warfarin-containing regimens)
Study: 17894654
Drug: Mitemcinal 10
Normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitemcinal 10 mg bid
Study: 17894654
Drug: Mitemcinal 20
Normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitemcinal 20 mg bid
Study: 17894654
Drug: Mitemcinal 30
Normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitemcinal 30 mg bid
Study: 17894654
Drug: Mitemcinal 20
Normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitemcinal 20 mg tid
Study: 15196109
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg kg(‐1) bolus followed by 2 microg kg(‐1) min(‐1) infusion)
Study: 12452304
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group 1, n=11)
Study: 12452304
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group 1) without cardiogenic shock
Study: 12452304
Drug: Primary angioplasty
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary angioplasty (group 2) and conservative treatment (group 1) in cardiogenic shock
Study: 7711987
Drug: Zetir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zetir (10 mg cetirizine dihydrochloride)
Study: 7711987
Drug: Zyrtek (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zyrtek (10 mg cetirizine dihydrochloride)
Study: 2570799
Drug: chlorpheniramine maleate,
Normalized name: Chlorpheniramine Maleate, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpheniramine maleate, 8 mg
Study: 720103
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.05 ml of Finalgon Strong Ointment
Study: 30694974
Drug: Combined histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined histamine H1 and H2 receptor antagonists (Blockade)
Study: 28637064
Drug: Glycopyrrolate (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.004 mg/kg IM)
Study: 28637064
Drug: Placebo (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.0 mL normal saline solution IM)
Study: 10075160
Drug: PENTA vaccine
Normalized name: Pentam
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENTA vaccine at 12 months
Study: 10075160
Drug: PENTA vaccine
Normalized name: Pentam
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENTA vaccine at 15 months
Study: 10075160
Drug: PENTA vaccine
Normalized name: Pentam
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PENTA vaccine at 18 months
Study: 7669467
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg kg‐1 i.v., followed by 5 micrograms kg‐1 min‐1
Study: 31544379
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg, 3 times a day) and Vitamin E (100 mg, once a day) for oral administration for 12 weeks
Study: 28408148
Drug: Brass wire
Normalized name: Brassica napus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brass wire ligature treatment with mandibular third molar germectomy (group A)
Study: 28408148
Drug: Brass wire
Normalized name: Brassica napus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brass wire ligature treatment without mandibular third molar germectomy (group B)
Study: 23419459
Drug: OnabotulinumtoxinA detrusor
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA detrusor injections
Study: 23419459
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no OnabotulinumtoxinA injections)
Study: 21233462
Drug: FAME therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAME therapy (family-mediated exercise therapy) for 8 weeks
Study: 21233462
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy with no formal input from family members (Control)
Study: 19436681
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 mg twice daily)
Study: 15361495
Drug: Diet excluding
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet excluding all foods to which they had raised IgG antibodies
Study: 15361495
Drug: Sham diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham diet excluding the same number of foods but not those to which they had antibodies
Study: 7979622
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg four times a day)
Study: 30670840
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Study: 28608496
Drug: Intravenously pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously pantoprazole 40 mg once daily
Study: 26244837
Drug: Gentamicin solution
Normalized name: gentamicin Injectable Solution
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin solution (Group 2)
Study: 26244837
Drug: Clindamycin solution
Normalized name: clindamycin Oral Solution
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin solution (Group 3)
Study: 23280086
Drug: ALL‐2 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALL‐2 regimen (cytarabine 3 g/m(2) daily for 5 days with mitoxantrone 80 mg/m(2))
Study: 23280086
Drug: L‐20 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐20 regimen (standard 4‐drug induction)
Study: 23280086
Drug: L‐20 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐20 regimen
Study: 9093646
Drug: Pancuronium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.10 mg.kg‐1)
Study: 9093646
Drug: Atracurium (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.50 mg.kg‐1)
Study: 9093646
Drug: Atracurium (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.16 mg.kg‐1) after Pancuronium
Study: 9093646
Drug: Pancuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.03 mg.kg‐1)
Study: 1868024
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine
Study: 1868024
Drug: 3-drug combination
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-drug combination alternating with the 2-drug combination every other month
Study: 7133974
Drug: Pirprofen 400
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 400 mg
Study: 23265757
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of saline four hourly (single dose group)
Study: 23265757
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of amoxycillin 0.5 g four hourly (short course group)
Study: 20608879
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch with two drug-containing layers (20% and 80% concentrations) and a barrier layer (14% thickness)
Study: 19185242
Drug: epi‐Shugarcaine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: epi‐Shugarcaine solution (epinephrine 0.025% and lidocaine 0.75% in fortified balanced salt solution [BSS Plus])
Study: 19185242
Drug: Lundberg and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lundberg and Behndig's intracameral dilation solution (cyclopentolate 0.1%, phenylephrine 1.5%, and lidocaine 1%)
Study: 17332444
Drug: Mental practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental practice (MP) sessions, 30 minutes, 2 days/week for 6 weeks, directly after therapy
Study: 15026102
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus an individually tailored and administered educational intervention promoting safe-driving strategies
Study: 10649160
Drug: Twice-weekly fetal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly fetal surveillance
Study: 9150703
Drug: Lanreotide (LRT)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LRT) 0.04 g i.m. once every 2 weeks for 3 months
Study: 9150703
Drug: Water injection
Normalized name: electroly,inj/dextrose-water INJECTION AMPUL (ML)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water injection i.m. once every 2 weeks for 3 months (Control)
Study: 8103874
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (100 mg over 3 h)
Study: 1919305
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg administered 10 minutes after 5 mg epidural morphine
Study: 30265882
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) - 3 doses of 2g at 4, 10, and 16 hours postoperatively
Study: 30265882
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) - 3 doses of 1g at 6, 12, and 18 hours postoperatively
Study: 30265882
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and intravenous TXA)
Study: 20379947
Drug: Quality control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality control assessments of explanted implant failures
Study: 18342952
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with antidepressants
Study: 16377699
Drug: BAL8557 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (100 mg loading dose followed by 50 mg maintenance dose of BAL4815)
Study: 16377699
Drug: BAL8557 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (200 mg loading dose followed by 100 mg maintenance dose of BAL4815)
Study: 12729001
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture (5.6 g twice daily)
Study: 1528643
Drug: Acellular pertussis-diphtheria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis-diphtheria tetanus toxoids vaccine (APDT)
Study: 1528643
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell DTP vaccine
Study: 26923773
Drug: Carprofen (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (2.2 mg/kg per os every 12 hours for 7 days)
Study: 26923773
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel capsule (per os every 12 hours for 7 days)
Study: 22382633
Drug: PegIFNα‐2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2a (180 μg) plus ribavirin
Study: 22382633
Drug: PegIFNα‐2b (60-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin
Study: 22382633
Drug: PegIFNα‐2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2a (180 μg) plus ribavirin in IL28B TT genotype patients
Study: 22382633
Drug: PegIFNα‐2b (60-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin in IL28B TT genotype patients
Study: 22382633
Drug: PegIFNα‐2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2a (180 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Study: 22382633
Drug: PegIFNα‐2b (60-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2b (60-150 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years